Oculis (NASDAQ:OCS) Shares Gap Up – Should You Buy?

Oculis Holding AG (NASDAQ:OCS)’s share price gapped up prior to trading on Friday . The stock had previously closed at $18.70, but opened at $20.35. Oculis shares last traded at $20.41, with a volume of 64,061 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on OCS shares. Chardan Capital reiterated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Oculis presently has a consensus rating of “Buy” and an average price target of $28.80.

Oculis Stock Up 10.8 %

The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $839.24 million, a price-to-earnings ratio of -10.74 and a beta of -0.33. The firm’s 50 day moving average price is $16.38 and its two-hundred day moving average price is $13.87.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.